Joel Greenblatt’s Arbutus Biopharma ABUS Stock Holding History

Joel Greenblatt’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,321	Closed	-$77.9K	–	1792
2026 Q1	$77.9K	Buy	+17,321	New	+$75.7K	﹤0.01%	1731

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Joel Greenblatt's ABUS Position: Q2 2026 in Review

Joel Greenblatt sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 17,321 shares — an estimated $77.9K sold.

Joel Greenblatt first reported a position in ABUS in Q1 2026 and held it in 1 quarter. The position peaked at $77.9K in Q1 2026. 175 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Joel Greenblatt reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
Joel Greenblatt sold 17,321 Arbutus Biopharma shares in Q2 2026, an estimated $77.9K.
Joel Greenblatt first reported a position in Arbutus Biopharma in Q1 2026 and held it in 1 quarter.
Joel Greenblatt's Arbutus Biopharma position peaked at $77.9K in Q1 2026.
175 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.